The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?

References

• Plotkin SA. Vaccines correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47:401–9. doi:10.1086/589862. PMID:18558875.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Complex correlates of protection after vaccination. Clin Infect Dis. 2013;56:1458–65. doi:10.1093/cid/cit048. PMID:23386629.
   PubMed Web of Science ®Google Scholar
• Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Rev Vaccines. 2016;15:967–76. doi:10.1586/14760584.2016.1164046. PMID:26954563.
   PubMed Web of Science ®Google Scholar
• Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: A review. Vaccine. 2017;[Epub ahead of print]. pii: S0264–410X(17)30970-2. doi:10.1016/j.vaccine.2017.07.062.
   Web of Science ®Google Scholar
• van der Meer JW, Zegers BJ. Agammaglobulinaemia. Neth J Med 1994;45:250–6. PMID:7838240
   PubMedGoogle Scholar
• Madani G, Heiner DC. Antibody transmission from mother to fetus. Curr Opin Immunol 1989;1:1157–64. doi:10.1016/0952-7915(89)90009-5. PMID:2679753.
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM. Immunological memory not equal protective immunity. Cell Mol Life Sci. 2012;69:1635–40. doi:10.1007/s00018-012-0972-y. PMID:22481438.
   PubMed Web of Science ®Google Scholar
• Hsu JL, Safdar N. Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases. Infect Dis Clin North Am. 2011;25:773–88. doi:10.1016/j.idc.2011.07.005. PMID:22054755.
   PubMed Web of Science ®Google Scholar
• Herder M, Hatchette TF, Halperin SA, Langley JM. Against vaccine assay secrecy. Hum Vaccin Immunother. 2015;11:498–503. doi:10.4161/21645515.2014.980194. PMID:25826194.
   PubMed Web of Science ®Google Scholar
• Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, Rappaport R, Eldridge JH, Gruber WC. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol. 2008;15:1042–53. doi:10.1128/CVI.00397-07. PMID:18448618.
   PubMed Web of Science ®Google Scholar
• Goodell V, dela Rosa C, Slota M, MacLeod B, Disis ML. Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses. BMC Immunol. 2007;8:21. doi:10.1186/1471-2172-8-21. PMID:17850666.
   PubMed Web of Science ®Google Scholar
• Macchia I, Urbani F, Proietti E. Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays. Biomed Res Int. 2013;2013:726239. doi:10.1155/2013/726239. PMID:24195078.
   PubMedGoogle Scholar
• Coughlan L, Lambe T. Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and Challenges. Vaccines (Basel). 2015;3:293–319. doi:10.3390/vaccines3020293. PMID:26343189.
   PubMed Web of Science ®Google Scholar
• Calarota SA, Aberle JH, Puchhammer-Stockl E, Baldanti F. Approaches for monitoring of non virus-specific and virus-specific T-cell response in solid organ transplantation and their clinical applications. J Clin Virol. 2015;70:109–19. doi:10.1016/j.jcv.2015.07.299. PMID:26305832.
   PubMed Web of Science ®Google Scholar
• Manini I, Trombetta CM, Lazzeri G, Pozzi T, Rossi S, Montomoli E. Egg-Independent Influenza Vaccines and Vaccine Candidates. Vaccines (Basel). 2017;5(3):1–8. pii: E18. doi: 10.3390/vaccines5030018 PMID:28718786
   PubMed Web of Science ®Google Scholar
• Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov. 2015;14:167–82. doi:10.1038/nrd4529. PMID:25722244.
   PubMed Web of Science ®Google Scholar
• Tauraso NM, O'Brien TC, Seligman EB. Jr. Problems of influenza virus vaccine standardization. Bull World Health Organ 1969;41:497–506. PMID:5309464
   PubMed Web of Science ®Google Scholar
• Stephenson I, Heath A, Major D, Newman RW, Hoschler K, Junzi W, Katz JM, Weir JP, Zambon MC, Wood JM. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis. 2009;15:1252–9. doi:10.3201/eid1508.081754. PMID:19751587.
   PubMed Web of Science ®Google Scholar
• Wood JM, Gaines-Das RE, Taylor J, Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 1994;12:167–74. doi:10.1016/0264-410X(94)90056-6. PMID:8147099.
   PubMed Web of Science ®Google Scholar
• Wood JM, Major D, Heath A, Newman RW, Höschler K, Stephenson I, Clark T, Katz JM, Zambon MC. Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard. Vaccine. 2012;30:210–7. doi:10.1016/j.vaccine.2011.11.019. PMID:22100887.
   PubMed Web of Science ®Google Scholar
• Wood JM, Montomoli E, Newman RW, Daas A, Buchheit KH, Terao E. Collaborative study on influenza vaccine clinical trial serology - part 2: reproducibility study. Pharmeur Bio Sci Notes. 2011;2011:36–54. PMID:21619855
   PubMedGoogle Scholar
• Laurie KL, Engelhardt OG, Wood J, Heath A, Katz JM, Peiris M, Hoschler K, Hungnes O, Zhang W, Van Kerkhove MD, et al. International Laboratory Comparison of Influenza Microneutralization Assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) Influenza Viruses by CONSISE. Clin Vaccine Immunol. 2015;22:957–64. doi:10.1128/CVI.00278-15. PMID:26108286.
   PubMed Web of Science ®Google Scholar
• Zacour M, Ward BJ, Brewer A, Tang P, Boivin G, Li Y, Warhuus M, McNeil SA, LeBlanc JJ, Hatchette TF, et al. Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories. Clin Vaccine Immunol. 2016;23:236–42. doi:10.1128/CVI.00613-15. PMID:26818953.
   PubMed Web of Science ®Google Scholar
• Smith W, Westwood MA, Westwood JC, Belyavin G. Spontaneous mutation of influenza virus A during routine egg passage. Br J Exp Pathol 1951;32:422–32. PMID:14886504
   PubMedGoogle Scholar
• Lugovtsev VY, Vodeiko GM, Levandowski RA. Mutational pattern of influenza B viruses adapted to high growth replication in embryonated eggs. Virus Res. 2005;109:149–57. doi:10.1016/j.virusres.2004.11.016. PMID:15763145.
   PubMed Web of Science ®Google Scholar
• Gatherer D. Passage in egg culture is a major cause of apparent positive selection in influenza B hemagglutinin. J Med Virol. 2010;82:123–7. doi:10.1002/jmv.21648. PMID:19950248.
   PubMed Web of Science ®Google Scholar
• Raymond DD, Stewart SM, Lee J, Ferdman J, Bajic G, Do KT, Ernandes MJ, Suphaphiphat P, Settembre EC, Dormitzer PR, et al. Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nat Med. 2016;22:1465–9. doi:10.1038/nm.4223. PMID:27820604.
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Sabaiduc S, Chambers C, Eshaghi A, Gubbay JB, Krajden M, Drews SJ, Martineau C, De Serres G, Dickinson JA, et al. Mutations acquired during cell culture isolation may affect antigenic characterisation of influenza A(H3N2) clade 3C.2a viruses. Euro Surveill. 2016;21:30112. doi:10.2807/1560-7917.ES.2016.21.3.30112. PMID:26836031.
   PubMedGoogle Scholar
• Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, Fonseca K, Winter AL, Gubbay JB, Krajden M, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9:e92153. doi:10.1371/journal.pone.0092153. PMID:24667168.
   PubMed Web of Science ®Google Scholar
• Wu NC, Zost SJ, Thompson AJ, Oyen D, Nycholat CM, McBride R, Paulson JC, Hensley SE, Wilson IA. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog. 2017;13:e1006682. doi:10.1371/journal.ppat.1006682. PMID:29059230.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm. 2015.
   Google Scholar
• Weir JP, Gruber MF. An overview of the regulation of influenza vaccines in the United States. Influenza Other Respir Viruses. 2016;10:354–60. doi:10.1111/irv.12383. PMID:27426005.
   PubMed Web of Science ®Google Scholar
• Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972;70:767–77. doi:10.1017/S0022172400022610. PMID:4509641.
   PubMedGoogle Scholar
• Fox JP, Cooney MK, Hall CE, Foy HM. Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol 1982;116:228–42. doi:10.1093/oxfordjournals.aje.a113408. PMID:7114034.
   PubMed Web of Science ®Google Scholar
• Al-Khayatt R, Jennings R, Potter CW. Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis. J Hyg (Lond) 1984;93:301–12. doi:10.1017/S0022172400064834. PMID:6389697.
   PubMedGoogle Scholar
• Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol. 2010;10:18. doi:10.1186/1471-2288-10-18. PMID:20210985.
   PubMed Web of Science ®Google Scholar
• Ng S, Fang VJ, Ip DK, Chan KH, Leung GM, Peiris JS, Cowling BJ. Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J Infect Dis. 2013;208:1320–4. doi:10.1093/infdis/jit372. PMID:23908481.
   PubMed Web of Science ®Google Scholar
• Zhao X, Fang VJ, Ohmit SE, Monto AS, Cook AR, Cowling BJ. Quantifying Protection Against Influenza Virus Infection Measured by Hemagglutination-inhibition Assays in Vaccine Trials. Epidemiology. 2016;27:143–51. doi:10.1097/EDE.0000000000000402. PMID:26427723.
   PubMed Web of Science ®Google Scholar
• Verschoor CP, Singh P, Russell ML, Bowdish DM, Brewer A, Cyr L, Ward BJ, Loeb M. Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. PLoS One. 2015;10:e0131531. doi:10.1371/journal.pone.0131531. PMID:26107625.
   PubMed Web of Science ®Google Scholar
• Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011;30:1081–5. doi:10.1097/INF.0b013e3182367662. PMID:21983214.
   PubMed Web of Science ®Google Scholar
• Tsang TK, Cauchemez S, Perera RA, Freeman G, Fang VJ, Ip DK, Leung GM, Malik Peiris JS, Cowling BJ. Association between antibody titers and protection against influenza virus infection within households. J Infect Dis. 2014;210:684–92. doi:10.1093/infdis/jiu186. PMID:24676208.
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis. 2011;204:1879–85. doi:10.1093/infdis/jir661. PMID:21998477.
   PubMed Web of Science ®Google Scholar
• de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel). 2003;115:63–73. PMID:15088777
   PubMedGoogle Scholar
• Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24:1159–69. doi:10.1016/j.vaccine.2005.08.105. PMID:16213065.
   PubMed Web of Science ®Google Scholar
• Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng NY, Nishtala M, Wrammert J, Smith K, James JA, et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest. 2011;121:3109–19. doi:10.1172/JCI57834. PMID:21785218.
   PubMed Web of Science ®Google Scholar
• Dunning AJ, DiazGranados CA, Voloshen T, Hu B, Landolfi VA, Talbot HK. Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial. Clin Vaccine Immunol. 2016;23:228–35. doi:10.1128/CVI.00604-15. PMID:26762363.
   PubMed Web of Science ®Google Scholar
• Ferdinands JM, Fry AM, Reynolds S, Petrie J, Flannery B, Jackson ML, Belongia EA. Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011–12 through 2014–15. Clin Infect Dis. 2017;64:544–50. PMID:28039340
   PubMed Web of Science ®Google Scholar
• Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945–52. doi:10.1056/NEJMoa0906453. PMID:19745214.
   PubMed Web of Science ®Google Scholar
• Jegaskanda S, Luke C, Hickman HD, Sangster MY, Wieland-Alter WF, McBride JM, Yewdell JW, Wright PF, Treanor J, Rosenberger CM, et al. Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge. J Infect Dis. 2016;214:945–52. doi:10.1093/infdis/jiw262. PMID:27354365.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Palese P, Wilson PC, Ravetch JV. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest. 2016;126:605–10. doi:10.1172/JCI84428. PMID:26731473.
   PubMed Web of Science ®Google Scholar
• Johansson BE, Cox MM. Influenza viral neuraminidase: the forgotten antigen. Expert Rev Vaccines. 2011;10:1683–95. doi:10.1586/erv.11.130. PMID:22085172.
   PubMed Web of Science ®Google Scholar
• Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, Bristol T, Fargis S, Risos K, Powers JH, et al. Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model. MBio. 2016;7:e00417–16. doi:10.1128/mBio.00417-16. PMID:27094330.
   PubMed Web of Science ®Google Scholar
• Wagar LE, Rosella L, Crowcroft N, Lowcock B, Drohomyrecky PC, Foisy J, Gubbay J, Rebbapragada A, Winter AL, Achonu C, et al. Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: implications for vaccination. PLoS One. 2011;6:e28063. doi:10.1371/journal.pone.0028063. PMID:22132212.
   PubMed Web of Science ®Google Scholar
• Zens KD, Farber DL. Memory CD4 T cells in influenza. Curr Top Microbiol Immunol. 2015;386:399–421. PMID:25005927
   PubMed Web of Science ®Google Scholar
• Hufford MM, Kim TS, Sun J, Braciale TJ. The effector T cell response to influenza infection. Curr Top Microbiol Immunol. 2015;386:423–55. PMID:25033753
   PubMed Web of Science ®Google Scholar
• Duvvuri VR, Moghadas SM, Guo H, Duvvuri B, Heffernan JM, Fisman DN, Wu GE, Wu J. Highly conserved cross-reactive CD4+ T-cell HA-epitopes of seasonal and the 2009 pandemic influenza viruses. Influenza Other Respir Viruses. 2010;4:249–58. doi:10.1111/j.1750-2659.2010.00161.x. PMID:20716156.
   PubMed Web of Science ®Google Scholar
• Hillaire ML, van Trierum SE, Kreijtz JH, Bodewes R, Geelhoed-Mieras MM, Nieuwkoop NJ, Fouchier RA, Kuiken T, Osterhaus AD, Rimmelzwaan GF. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J Gen Virol. 2011;92:2339–49. doi:10.1099/vir.0.033076-0. PMID:21653752.
   PubMed Web of Science ®Google Scholar
• van de Sandt CE, Hillaire ML, Geelhoed-Mieras MM, Osterhaus AD, Fouchier RA, Rimmelzwaan GF. Human Influenza A Virus-Specific CD8+ T-Cell Response Is Long-lived. J Infect Dis. 2015;212:81–5. doi:10.1093/infdis/jiv018. PMID:25583167.
   PubMed Web of Science ®Google Scholar
• Hayward AC, Wang L, Goonetilleke N, Fragaszy EB, Bermingham A, Copas A, Dukes O, Millett ER, Nazareth I, Nguyen-Van-Tam JS, et al. Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. Am J Respir Crit Care Med. 2015;191:1422–31. doi:10.1164/rccm.201411-1988OC.
   PubMed Web of Science ®Google Scholar
• Altenburg AF, Rimmelzwaan GF, de Vries RD. Virus-specific T cells as correlate of (cross-)protective immunity against influenza. Vaccine. 2015;33:500–6. doi:10.1016/j.vaccine.2014.11.054. PMID:25498210.
   PubMed Web of Science ®Google Scholar
• Brown DM, Dilzer AM, Meents DL, Swain SL. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol. 2006;177:2888–98. doi:10.4049/jimmunol.177.5.2888. PMID:16920924.
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Fu TM, Deck RR, Friedman A, Guan L, DeWitt C, Liu X, Wang S, Liu MA, Donnelly JJ, et al. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol. 1998;72:5648–53. PMID:9621023
   PubMed Web of Science ®Google Scholar
• Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature. 1994;367:425–8. doi:10.1038/367425a0. PMID:8107800.
   PubMed Web of Science ®Google Scholar
• Lin J, Somanathan S, Roy S, Calcedo R, Wilson JM. Lung homing CTLs and their proliferation ability are important correlates of vaccine protection against influenza. Vaccine. 2010;28:5669–75. doi:10.1016/j.vaccine.2010.06.053. PMID:20600493.
   PubMed Web of Science ®Google Scholar
• McKinstry KK, Dutton RW, Swain SL, Strutt TM. Memory CD4 T cell-mediated immunity against influenza A virus: more than a little helpful. Arch Immunol Ther Exp (Warsz). 2013;61:341–53. doi:10.1007/s00005-013-0236-z. PMID:23708562.
   PubMed Web of Science ®Google Scholar
• Spensieri F, Borgogni E, Zedda L, Bardelli M, Buricchi F, Volpini G, Fragapane E, Tavarini S, Finco O, Rappuoli R, et al. Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses. Proc Natl Acad Sci U S A. 2013;110:14330–5. doi:10.1073/pnas.1311998110. PMID:23940329.
   PubMed Web of Science ®Google Scholar
• Bentebibel SE, Lopez S, Obermoser G, Schmitt N, Mueller C, Harrod C, Flano E, Mejias A, Albrecht RA, Blankenship D, et al. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med. 2013;5:176ra32. doi:10.1126/scitranslmed.3005191. PMID:23486778.
   PubMed Web of Science ®Google Scholar
• Thomas PG, Brown SA, Morris MY, Yue W, So J, Reynolds C, Webby RJ, Doherty PC. Physiological numbers of CD4+ T cells generate weak recall responses following influenza virus challenge. J Immunol. 2010;184:1721–7. doi:10.4049/jimmunol.0901427. PMID:20061406.
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012;18:274–80. doi:10.1038/nm.2612. PMID:22286307.
   PubMed Web of Science ®Google Scholar
• Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013;19:1305–12. doi:10.1038/nm.3350. PMID:24056771.
   PubMed Web of Science ®Google Scholar
• Murasko DM, Bernstein ED, Gardner EM, Gross P, Munk G, Dran S, Abrutyn E. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol. 2002;37:427–39. doi:10.1016/S0531-5565(01)00210-8. PMID:11772530.
   PubMed Web of Science ®Google Scholar
• McElhaney JE. Influenza vaccine responses in older adults. Ageing Res Rev. 2011;10:379–88. doi:10.1016/j.arr.2010.10.008. PMID:21055484.
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Kuchel GA, Zhou X, Swain SL, Haynes L. T-Cell Immunity to Influenza in Older Adults: A Pathophysiological Framework for Development of More Effective Vaccines. Front Immunol. 2016;7:41. doi:10.3389/fimmu.2016.00041. PMID:26941738.
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, Laframboise C, Al Adhami MJ, Khaliq Y, Seguin I, et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 2004;22:3136–43. doi:10.1016/j.vaccine.2004.01.058. PMID:15297066.
   PubMed Web of Science ®Google Scholar
• Lartey S, Pathirana RD, Zhou F, Jul-Larsen Å, Montomoli E, Wood J, Cox RJ. Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains. Hum Vaccin Immunother. 2015;11:1654–62. doi:10.1080/21645515.2015.1048939. PMID:26009966.
   PubMed Web of Science ®Google Scholar
• Cao W, Kim JH, Reber AJ, Hoelscher M, Belser JA, Lu X, Katz JM, Gangappa S, Plante M, Burt DS, et al. Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice. Vaccine. 2017;35:3318–25. doi:10.1016/j.vaccine.2017.05.004. PMID:28499553.
   PubMed Web of Science ®Google Scholar
• Hemann EA, Kang SM, Legge KL. Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination. J Immunol. 2013;191:2486–94. doi:10.4049/jimmunol.1300954. PMID:23885108.
   PubMed Web of Science ®Google Scholar
• Landry N, Pillet S, Favre D, Poulin JF, Trépanier S, Yassine-Diab B, Ward BJ. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin Immunol. 2014;154:164–77. doi:10.1016/j.clim.2014.08.003. PMID:25128897.
   PubMed Web of Science ®Google Scholar
• Pillet S, Aubin E, Trepanier S, Bussière D, Dargis M, Poulin JF, Yassine-Diab B, Ward BJ, Landry N. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. Clin Immunol. 2016;168:72–87. doi:10.1016/j.clim.2016.03.008. PMID:26987887.
   PubMed Web of Science ®Google Scholar
• van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A. Harmonization of immune biomarker assays for clinical studies. Sci Transl Med. 2011;3:108ps44. doi:10.1126/scitranslmed.3002785. PMID:22072636.
   PubMed Web of Science ®Google Scholar
• Britten CM, van der Burg SH, Gouttefangeas C. A framework for T cell assays. Oncotarget. 2015;6:35143–4. PMID:26506424
   PubMedGoogle Scholar
• Kleinsteuber K, Corleis B, Rashidi N, Nchinda N, Lisanti A, Cho JL, Medoff BD, Kwon D, Walker BD. Standardization and quality control for high-dimensional mass cytometry studies of human samples. Cytometry A. 2016;89:903–13. doi:10.1002/cyto.a.22935. PMID:27575385.
   PubMedGoogle Scholar
• Engelhardt OG. http://www.who.int/immunization/research/meetings_workshops/Othmar_Engelhardt_Chicago_August_2016.pdf National Institute for Biological Standards and Control (NISBC). 2016.
   Google Scholar
• European Medicines Agency. Guideline on influenza vaccines - non-clinical and clinical module. 2016. EMA/CHMP/VWP/457259/20142014.
   Google Scholar
• Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, Ben-Yedidia T. Safety and immunogenicity of multimeric-001-a novel universal influenza vaccine. J Clin Immunol. 2012;32:595–603. doi:10.1007/s10875-011-9632-5. PMID:22318394.
   PubMed Web of Science ®Google Scholar
• Krammer F. Novel universal influenza virus vaccine approaches. Curr Opin Virol. 2016;17:95–103. doi:10.1016/j.coviro.2016.02.002. PMID:26927813.
   PubMed Web of Science ®Google Scholar
• Hegde NR. Cell culture-based influenza vaccines: A necessary and indispensable investment for the future. Hum Vaccin Immunother. 2015;11:1223–34. doi:10.1080/21645515.2015.1016666. PMID:25875691.
   PubMed Web of Science ®Google Scholar
• Nakowitsch S, Waltenberger AM, Wressnigg N, et al. Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines. Biotechnol J. 2014;9:405–14. doi:10.1002/biot.201300225. PMID:24323790.
   PubMed Web of Science ®Google Scholar
• Ramanunninair M, Le J, Onodera S, Fulvini AA, Pokorny BA, Silverman J, Devis R, Arroyo JM, He Y, Boyne A, et al. Molecular signature of high yield (growth) influenza a virus reassortants prepared as candidate vaccine seeds. PLoS One. 2013;8:e65955. doi:10.1371/journal.pone.0065955. PMID:23776579.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Pediatr Infect Dis J. 2012;31:494–500. doi:10.1097/INF.0b013e31824bb179. PMID:22301476.
   PubMed Web of Science ®Google Scholar
• Carbone V, Schneider EK, Rockman S, Baker M, Huang JX, Ong C, Cooper MA, Yuriev E, Li J, Velkov T. Molecular Characterisation of the Haemagglutinin Glycan-Binding Specificity of Egg-Adapted Vaccine Strains of the Pandemic 2009 H1N1 Swine Influenza A Virus. Molecules. 2015;20:10415–34. doi:10.3390/molecules200610415. PMID:26056814.
   PubMed Web of Science ®Google Scholar
• Parker L, Wharton SA, Martin SR, Cross K, Lin Y, Liu Y, Feizi T, Daniels RS, McCauley JW. Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses. J Gen Virol. 2016;97:1333–44. doi:10.1099/jgv.0.000457. PMID:26974849.
   PubMed Web of Science ®Google Scholar
• Nicolson C, Harvey R, Engelhardt OG, Robertson JS. The Ability of a Non-Egg Adapted (Cell-Like) A(H1N1)pdm09 Virus to Egg-Adapt at HA Loci Other than 222 and 223 and Its Effect on the Yield of Viral Protein. PLoS One. 2016;11:e0166761. doi:10.1371/journal.pone.0166761. PMID:27861557.
   PubMed Web of Science ®Google Scholar
• D'Aoust MA, Lavoie PO, Couture MM, Trépanier S, Guay JM, Dargis M, Mongrand S, Landry N, Ward BJ, Vézina LP. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J. 2008;6:930–40. doi:10.1111/j.1467-7652.2008.00384.x. PMID:19076615.
   PubMed Web of Science ®Google Scholar
• Dunkle LM, Izikson R, Patriarca P, et al. Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older. N Engl J Med. 2017;376:2427–36. doi:10.1056/NEJMoa1608862. PMID:28636855.
   PubMed Web of Science ®Google Scholar
• Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis. 2010;51:997–1004. doi:10.1086/656578. PMID:20868284.
   PubMed Web of Science ®Google Scholar
• Chen Z, Aspelund A, Jin H. Stabilizing the glycosylation pattern of influenza B hemagglutinin following adaptation to growth in eggs. Vaccine. 2008;26:361–71. doi:10.1016/j.vaccine.2007.11.013. PMID:18079027.
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635–45. doi:10.1056/NEJMoa1315727. PMID:25119609.
   PubMed Web of Science ®Google Scholar
• Amato-Gauci A, Zucs P, Snacken R, Ciancio B, Lopez V, Broberg E, Penttinen P, Nicoll A. European Influenza Surveillance Network EISN. Surveillance trends of the 2009 influenza A(H1N1) pandemic in Europe. Euro Surveill. 2011;16(26):1–11. pii: 19903. doi:10.2807/ese.16.26.19903-en.
   Google Scholar
• Garcia-Sastre A. Systems vaccinology informs influenza vaccine immunogenicity. Proc Natl Acad Sci U S A. 2016;113:1689–91. doi:10.1073/pnas.1525361113. PMID:26842838.
   PubMed Web of Science ®Google Scholar
• Rodrigues CMC, Pinto MV, Sadarangani M, Plotkin SA. Whither vaccines? J Infect. 2017;74 Suppl 1:S2–S9. doi:10.1016/S0163-4453(17)30184-6. PMID:28646957.
   PubMedGoogle Scholar